Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biallelic ARID1A Alterations : A Promising Novel Biomarker for Risk Stratification and Management in Pediatric Malignant Hepatocellular Tumors.

The American journal of surgical pathology - 1 Sept 2026

Patel Kalyani R, Urbicain Martin, Sarabia Stephen F, Perez Cintia R, Major Angela M, Fisher Kevin E, Roy Angshumoy, Askin Frederic, Heczey Andras, Espinoza Andres F, Vasudevan Sanjeev A, Sumazin Pavel, Lopez-Terrada Dolores H

Abstract excerpt

Somatic mutations and copy number alterations of the adenine-thymine (AT)-rich interactive domain-containing protein 1A ( ARID1A ), a tumor suppressor gene, are associated with poor prognosis in many cancers, including adult hepatocellular carcinomas (HCC). In this study, ARID1A protein expression, clinicopathologic features, and outcomes were investigated in 59 pediatric malignant hepatocellular tumors (2004 to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Hepatocellular

Share to DNA-Binding Proteins

Share to DNA Copy Number Variations

Share to Liver Neoplasms

Share to Predictive Value of Tests

Share to Risk Assessment

Source

Identifiers

PMID: 42299071
DOI: 10.1097/PAS.0000000000002578

Genes

ARID1A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biallelic ARID1A Alterations : A Promising Novel Biomarker for Risk Stratification and Management in Pediatric Malignant Hepatocellular Tumors.PMID 42299071Read ↗

Low ARID1A Expression is Associated with Poor Prognosis in Hepatocellular CarcinomaSemantic proximity Read ↗

ARID1A mutation is associated with an immunosuppressive microenvironment and poor prognosis in hepatocellular carcinoma: An integrated bioinformatics analysis.Semantic proximity Read ↗

ARID1A mutations in cancer development: mechanism and therapy.Semantic proximity Read ↗

Comprehensive Landscape of ARID Family Members and Their Association with Prognosis and Tumor Microenvironment in Hepatocellular CarcinomaSemantic proximity Read ↗

ARID1A and Its Impact Across the Hallmarks of CancerSemantic proximity Read ↗

ARID1A in cancer: Friend or foe?Semantic proximity Read ↗

Characterization of pediatric hepatocellular carcinoma reveals genomic heterogeneity and diverse signaling pathway activationSemantic proximity Read ↗

ARID1A Variations in Cholangiocarcinoma: Clinical Significances and Molecular MechanismsSemantic proximity Read ↗

Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults.Semantic proximity Read ↗

ARID1A alterations function as a biomarker for longer progression-free survival after anti-PD-1/PD-L1 immunotherapySemantic proximity Read ↗

ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular CarcinomaSemantic proximity Read ↗

Decreased expression of ARID1A associates with poor prognosis and promotes metastases of hepatocellular carcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.